AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

SYNAIRGEN PLC

Major Shareholding Notification Aug 21, 2020

7941_mrq_2020-08-21_8d165357-c6a2-45d8-8403-8f44002a5750.html

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 8824W

Synairgen plc

21 August 2020

Synairgen plc

("Synairgen" or the "Company")

Holding(s) in Company

Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 21 August 2020 that Leonard Licht, a private investor, now holds 7,375,000 ordinary shares of 1 pence each in the capital of the Company, representing 4.93% of the Company's issued share capital.

Enquiries:

Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)

John Ward (Finance Director)
finnCap - nominated adviser and broker +44 (0) 20 7220 0500
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)
Consilium Strategic Communications - financial media and investor relations adviser +44 (0) 20 3709 5700
Mary-Jane Elliott, Sue Stuart, Olivia Manser

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

HOLFLFFRTRILFII

Talk to a Data Expert

Have a question? We'll get back to you promptly.